Malignant Uterine Corpus Neoplasm — Trials

Malignant Uterine Corpus Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,571 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 411
Recruiting: 226
Ph III recruiting: 25
Growth YoY: +3.1%
Industry share: 31%
Top sponsor: National Cancer Institute (NCI)
Termination share: 27.6%
Trials / 1,000 deaths: 50.2 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (168)

clinicaltrialsPublishedShowing 101–121 of 121 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02285192	Positron Lymphography Via Intracervical 18F-FDG Injection for Pre-surgical Lymphatic Mapping in Stage IB1 Cervical Cancer and High-grade Endometrial Cancer	active not recruiting	Phase 1	42	Memorial Sloan Kettering Cancer CenterOTHER	1	Dec 30, 2025	clinicaltrials
NCT05856981	Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors	recruiting	Phase 1	130	Sairopa B.V.INDUSTRY	3	Dec 17, 2025	clinicaltrials